CMTM1

Across TCGA pan-cancer cohorts, CMTM1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CMTM1 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CMTM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMTM1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC and HNSC are the cancer types where CMTM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.108	0.469	.011	14	view →
HNSC	DFS	Tertile	III,IV	0.929	0.632	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CMTM1–PDAC (DFS)

Open the PDAC breakdown →